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The failure of protein cancer biomarkers to reach




There is a plethora of published cancer biomarkers but the reality is that very few, if any, new circulating cancer
biomarkers have entered the clinic in the last 30 years. I here try to explain this apparent oxymoron by classifying
circulating cancer biomarkers into three categories: fraudulent reports (rare); true discoveries of biomarkers, that
then fail to meet the demands of the clinic; and false discoveries, which represent artifactual biomarkers. I further
provide examples of combinations of some known cancer biomarkers that can perform well in niche clinical
applications, despite individually being not useful.
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Background
There is wide debate recently as to why very few, if any,
new circulating cancer biomarkers have entered the
clinic in the last 30 years. The vast majority of clinically
useful cancer biomarkers were discovered between the
mid-1960s (for example, carcinoembryonic antigen,
CEA) and the early 1980s (for example, prostate-specific
antigen (PSA) and carbohydrate antigen 125 (CA125)).
It is true that major investments by both academia and
industry have been made in this area of investigation
but with very little return. One wonders why this hap-
pens in an era of spectacular technological advances.
Some argue that it is because the problem is very com-
plex and underestimated; others blame reasons such as
a lack of understanding of the pathobiology of cancer,
not enough funding, use of inappropriate samples for
discovery and validation, methodological limitations, and
so on [1,2].
Here, I will provide a brief and simplified analysis as
to why this may be happening. We should keep in mind
that the high failure rates in the biomarker field are no
different from those of therapeutics. But there is an
important difference. Therapeutics leading to relatively
small improvements in patient survival (weeks to
months) are likely to be marketed, while diagnostics
with relatively small improvements in patient diagnosis
or prognosis will likely fall by the wayside. Hence, simi-
lar advances in therapeutics and diagnostics can be
hailed as ‘successes’ in the former and ‘failures’ in the
latter.
Why do most biomarkers fail to reach the clinic?
One way of analyzing the apparent failures in diagnos-
tics is by classifying them into three distinct categories
(Figure 1). The first category of failing biomarkers
includes those that are based on fraudulent publications.
These are quite rare and, despite some highly-publicized
cases [3], fraud is not the major reason for failing
biomarkers.
The second and largest category of biomarkers that
never reach the clinic (and counted as failures) includes
those that have been discovered and validated by using
robust and reliable techniques (true discovery). These
biomarkers have successfully gone through the process
of discovery and validation, with reproducible and con-
cordant results between studies, from early to late
stages. However, these biomarkers fall short in their
ability to contribute decisively to patient care, except for
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providing some incremental, but clinically not essential,
information. For example, the urokinase plasminogen
activator/plasminogen activator inhibitor 1 (uPA/PAI 1)
combination of biomarkers has long been regarded as a
prognostic indicator of breast carcinoma, and many ret-
rospective and prospective studies and meta-analyses
have confirmed their prognostic value [4]. However,
they have not been widely adopted, especially in North
America, despite availability of excellent ELISA meth-
odologies for their measurement, because clinicians do
not seem to find this information necessary in deciding
how to treat their patients. Rather, they decide on treat-
ment options without this information, thus saving
costs. Clinicians usually prefer to over-treat some
patients, instead of using prognostic biomarkers with
less than perfect prediction. Imperfect prognostic bio-
markers could spare a fraction of patients from over-
treatment (true positives), but at the cost of not treating
some patients who could benefit from treatment (false
negatives). Another example is the tumor suppressor
p53. A search in PubMed for the term ‘p53 AND breast
cancer prognosis’ identifies 1470 papers, with the vast
majority confirming the prognostic value of p53, despite
its sparse use at the clinic, if any, due to the reasons
mentioned above (imperfect or weak prognostic value).
Other examples in this category include those biomar-
kers that have been discovered and validated thoroughly
by industry, and although found to have some use in clin-
ical prediction, the strength of their predictive ability is
not enough to persuade clinicians to use them, or clinical
practice guideline developers to recommend them. An
example is the novel ovarian cancer biomarker, B7-H4
(discovered by diaDexus Inc., San Francisco, CA, USA),
which was validated for its ability to diagnose ovarian
cancer [5]. Recently, an independent group confirmed
the diagnostic ability of this biomarker, but also demon-
strated that it is not better than the classical biomarker,
CA125 [6]. Consequently, the company that discovered
it, in the absence of a clear clinical utility, decided not to
market it. It is quite expensive to conduct the necessary






 Low prognostic/predictive value
 Information not necessary for 
clinical decision-making







Figure 1 Summary of reasons for biomarker failure to reach the clinic. Fraud is a very rare reason for biomarker failures; most biomarkers
represent true discoveries but their clinical characteristics are not good enough to be used at the clinic.
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clinical trials to obtain approval from the Food and Drug
Administration (FDA). There are numerous examples of
this sort in the literature, that is, of reasonable and work-
ing biomarkers that fall short of fulfilling a clear clinical
need and thus unlikely to be profitable if marketed.
There are also numerous examples of biomarkers
which have good sensitivity (>70% at 90% to 95% speci-
ficity) in detecting late carcinoma but poor sensitivity in
detecting disease in asymptomatic patients, especially at
the extremely high specificity required for screening (for
example, >99.5%, as is the case with ovarian carcinoma)
[6]. Consequently, none of the available ovarian cancer
biomarkers are suitable for screening, and it may be
unlikely that we will find any that can perform at these
clinically dictated and highly demanding specifications
(for example, >80% sensitivity for early and asympto-
matic disease, at ≥ 99.5% specificity; to achieve a reason-
able positive predictive value of ≥10%).
From this discussion, it can be concluded that a very
large number of candidate biomarkers have been discov-
ered, and have been confirmed by reliable methods to
provide diagnostic, prognostic or predictive information
in certain groups of patients. Unfortunately, this infor-
mation could not be translated into action for better
patient management and outcomes. So, work on bio-
markers is continuing. However, these biomarkers are
not recommended in practice guidelines for use in the
diagnosis or treatment of cancer [7], despite their statis-
tically significant (but clinically not useful) diagnostic,
predictive or prognostic information. Some examples of
well-validated biomarkers and their possible reason of
failure at the clinic are outlined in Table 1.
There is another group of biomarkers which may initi-
ally look highly promising (or even revolutionary) but
for which shortcomings have been identified, either at
the discovery or validation phase. For example, in my
previous commentary [8], I identified pre-analytical, ana-
lytical and post-analytical shortcomings of many
published biomarkers, which could invalidate the origi-
nal performance claims. This group of biomarkers
should be considered as ‘false discovery’. They will not
reach the clinic because the original performance claims
could not be independently reproduced in subsequent
validation studies.
Future prospects: how do we overcome failures?
In light of the analysis above, it can be concluded that the
failure of the myriad of biomarkers to reach the clinic,
excluding fraud, is either due to inadequate performance
in a clinical setting or to false discovery. There are at
least two ways to improve this situation. For those bio-
markers with a well-validated performance, but which
are not good enough for clinical use, it may be possible
to identify clinical scenarios for which the markers could
still help, in combination with other clinical or biomarker
data. For example, human epididymis protein 4 (HE4), a
new ovarian cancer biomarker, is not superior to CA125
for diagnosis of ovarian carcinoma [6] but is more speci-
fic. A combination of CA125 and HE4, through an algo-
rithm, was found to be useful in the investigation of
malignant versus benign pelvic masses [9]. Another test
combines serum CA125 with a few other proteomic bio-
markers which, individually, are not useful [10]. Both
tests have recently received FDA approval (2011; 2009,
respectively) for this specific application, thus reaching
the clinic, in combinations, but not individually. There
are examples of similar applications of otherwise not very
informative diagnostic biomarkers, such as in the investi-
gation of a computed tomography-positron emission
tomography-identified indeterminate lung masses, for
which a combination of already-known (but individually
not useful) biomarkers may help [11]. Similar examples
of ‘niche unmet needs’ include the identification of bio-
markers to assess the risk of malignancy for thyroid
nodules, specifically those with indeterminate results
after standard thyroid biopsy; identification of biomarkers
Table 1 Why well-validated biomarkers still fail to reach the clinic?
Clinical application Reason to Fail Example
Population screening and
diagnosis
• screening does not save lives; overdiagnosis/overtreatment PSA and prostate cancer screening
• too many false positives leading to unnecessary and invasive
confirmatory procedures
• CA 125 for ovarian cancer screening
• marker not profitable if marketed • B7-H4 for ovarian cancer diagnosis
Prognosis • weak prognostic value; clinicians prefer to overtreat instead of
undertreat
• p53 and uPA/PAI1 for breast cancer
• no effective therapy available • CA 19.9 for pancreatic cancer




• many false positives and false negatives • CA 15.3 for breast cancer
CA: carbohydrate antigen; PSA: prostate-specific antigen
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to improve on PSA’s specificity in screening (such as
prostate cancer gene 3) [12]; or, following diagnosis of
prostate cancer, identification of biomarkers that discern
between indolent versus aggressive prostate cancers.
Table 2 summarizes these niche unmet needs.
Another critical question is what could be done to
avoid false discovery. Recommendations for this problem
have been proposed elsewhere [2,8] and include under-
standing and avoidance of pre-analytical shortcomings;
careful study design to avoid bias [13,14]; use of analyti-
cal methodologies that are sensitive, specific and precise;
selecting appropriate samples (in numbers and quality)
and patient subgroups for validation; and application of
robust and rigorous statistics to avoid data over-fitting.
Conclusion
In theory, biomarkers can serve many clinical needs
from risk stratification to prognosis, screening, diagno-
sis, monitoring, patient subclassification, assessment of
drug toxicity and prediction of therapeutic response. To
bring biomarkers to the clinic, it is mandatory to show a
useful clinical application that is supported by the vali-
dation data. Only then will diagnostic companies invest
the necessary (and very significant) funds to conduct
multicenter clinical trials to show efficacy and receive
FDA approval. In conclusion, between the two groups of
biomarkers (false discovery and true discovery), the for-
mer can be considered a failure but the latter should
not. Distinguishing between these two categories is
important, since true discovery is based on good science
and statistically significant and reproducible data, while
false discovery is based on bad science. As shown with
examples, some fruits of true discovery can be combined
to design incremental but clinically useful and FDA-
approved improvements (Table 2). Eventually, the time
will likely come when biology and technology will
advance sufficiently to catalyze the needed and much
anticipated leap in cancer biomarkers.
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